Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026

NDA FilingSL1009Positive

AI Analysis

Summary

Saol Therapeutics announced FDA acceptance of a complete resubmission for SL1009 (DCA) for PDCD, a rare mitochondrial disease with no approved therapies, with a PDUFA decision date of December 30, 2026.

Outcome Details

FDA accepted resubmission as Class II response to August 27, 2025 CRL

Importance:7/10

Sentiment:

0.60

FDAPDUFAresubmissionCRLrare diseasemitochondrial diseaseunmet need

Read the original article

Published by PR Newswire Biotech on July 28, 2026 1:40 PM

Read Original